Compare Cytokinetics Inc (CYTK) vs M&T Bank Corporation (MTB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs M&T Bank Corporation — how do they compare? Cytokinetics Inc trades at $62.48 (market cap $8.62B), while M&T Bank Corporation trades at $216.6 (market cap $31.42B). The key difference: M&T Bank Corporation is far larger — about 3.6× Cytokinetics Inc's market cap, and M&T Bank Corporation pays a 2.76% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and M&T Bank Corporation for 100 Days on average.
| CYTK | MTB | |
|---|---|---|
Market Cap | $8.62B | $31.42B |
Volume | 2,594,626 | 1,438,219 |
Sector | Health | Financials |
52-Week High | $87.26 | $254.09 |
52-Week Low | $54.76 | $178.63 |
Typical Hold Time | 19 Days | 100 Days |
Enterprise Value | $8.72B | $47.77B |
Dividend Yield | — | 2.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
M&T Bank (MTB) trades at $216.60, down 0.98% with a bearish technical outlook. The stock shows strong fundamentals with a P/E of 11.52 and net income margin of 30.85%, supported by three consecutive quarterly earnings beats. Recent news highlights dividend strength and branch expansion, while cash flow trends show operational stability despite negative net cash flow in 2025.
MTB presents a value opportunity with attractive valuation metrics and consistent profitability, though technical weakness and declining cash flow warrant caution. Analyst consensus targets $258.92 (19.5% upside) with 31% buy ratings, but bearish technical signals and rising debt levels pose near-term risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
